Barr E S & Co. Takes $613,000 Position in CVS Health Corporation $CVS

Barr E S & Co. acquired a new stake in shares of CVS Health Corporation (NYSE:CVS) during the 4th quarter, Holdings Channel reports. The fund acquired 7,725 shares of the pharmacy operator’s stock, valued at approximately $613,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Canada Post Corp Registered Pension Plan raised its position in shares of CVS Health by 53.3% during the 4th quarter. Canada Post Corp Registered Pension Plan now owns 34,903 shares of the pharmacy operator’s stock valued at $2,770,000 after purchasing an additional 12,130 shares during the period. Lawood & Co. purchased a new position in CVS Health during the fourth quarter valued at $256,000. DNB Asset Management AS grew its stake in CVS Health by 17.6% during the fourth quarter. DNB Asset Management AS now owns 446,843 shares of the pharmacy operator’s stock valued at $35,461,000 after acquiring an additional 66,953 shares in the last quarter. Convergence Investment Partners LLC grew its stake in CVS Health by 263.8% during the fourth quarter. Convergence Investment Partners LLC now owns 26,079 shares of the pharmacy operator’s stock valued at $2,070,000 after acquiring an additional 18,911 shares in the last quarter. Finally, Northwestern Mutual Investment Management Company LLC grew its stake in CVS Health by 0.3% during the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 40,560 shares of the pharmacy operator’s stock valued at $3,219,000 after acquiring an additional 136 shares in the last quarter. 80.66% of the stock is currently owned by institutional investors.

Insider Activity at CVS Health

In related news, EVP Tilak Mandadi sold 69,551 shares of CVS Health stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the completion of the transaction, the executive vice president directly owned 10,133 shares of the company’s stock, valued at approximately $907,714.14. The trade was a 87.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.85% of the company’s stock.

CVS Health Stock Performance

Shares of NYSE:CVS opened at $95.95 on Friday. CVS Health Corporation has a 52 week low of $58.50 and a 52 week high of $98.43. The stock has a market capitalization of $122.42 billion, a P/E ratio of 42.27, a PEG ratio of 0.94 and a beta of 0.60. The firm has a fifty day simple moving average of $78.71 and a two-hundred day simple moving average of $78.59. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.78.

CVS Health (NYSE:CVS) last issued its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, topping analysts’ consensus estimates of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The business had revenue of $100.43 billion during the quarter, compared to analysts’ expectations of $94.99 billion. During the same period last year, the company posted $2.25 EPS. The business’s revenue was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, analysts expect that CVS Health Corporation will post 7.44 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, May 4th. Investors of record on Thursday, April 23rd were paid a dividend of $0.665 per share. The ex-dividend date of this dividend was Thursday, April 23rd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.8%. CVS Health’s payout ratio is currently 117.18%.

Key Stories Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Morgan Stanley raised its price target on CVS Health and kept an overweight rating, signaling confidence in further upside after the company’s stronger-than-expected quarterly results. Morgan Stanley Issues Positive Forecast for CVS Health (NYSE:CVS) Stock Price
• Positive Sentiment: Argus also lifted its outlook for CVS Health, adding to the wave of analyst support that may be helping shares move higher. Argus Issues Positive Forecast for CVS Health (NYSE:CVS) Stock Price
• Positive Sentiment: CVS reported solid Q1 2026 earnings recently, beating estimates on both revenue and adjusted EPS, which continues to drive investor optimism about execution and valuation. Here is Why CVS Health (CVS) is One of the Cheap Stocks to Buy For the Next 10 Years
• Positive Sentiment: CVS and WGU launched an online pre-pharmacy degree program to help build a stronger pharmacist pipeline, a move that could support long-term staffing and service growth. CVS Health® and WGU launch online pre-pharmacy degree program for future pharmacists nationwide
• Neutral Sentiment: CVS advanced its portfolio reset by selling Omnicare after bankruptcy court approval, which simplifies the business and removes an underperforming unit, but also confirms ongoing restructuring. CVS Refocuses On Core Health Platform With Omnicare Sale And Drone Rollout
• Neutral Sentiment: CVS also highlighted community and brand-building initiatives in Rhode Island, including its economic impact report and expanded WIC acceptance, which are positive for reputation but less likely to move the stock on their own. CVS Health’s Annual Impact in Rhode Island

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on CVS shares. HSBC raised their target price on shares of CVS Health from $83.00 to $85.00 and gave the company a “hold” rating in a research note on Tuesday, May 5th. Leerink Partners reaffirmed an “outperform” rating and set a $98.00 target price on shares of CVS Health in a research note on Thursday, March 5th. Deutsche Bank Aktiengesellschaft raised their target price on shares of CVS Health from $88.00 to $92.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. The Goldman Sachs Group raised their target price on shares of CVS Health from $95.00 to $97.00 and gave the company a “buy” rating in a research note on Thursday, February 12th. Finally, Barclays raised their target price on shares of CVS Health from $93.00 to $101.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. Twenty-two investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $98.08.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.